You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search

Vicriviroc



Articles on Vicriviroc

Merck Decides to Stop Development of Vicriviroc for Treatment of HIV
7/16/2010

Vicriviroc Fails to Beat Stiff Competition, Merck Will Not File for Treatment-experienced Approval
2/19/2010

Experimental CCR5 Antagonist Vicriviroc Appears Safe and Well Tolerated in HIV/HCV Coinfected Patients

1/12/2010

CCR5 Antagonist Vicriviroc Demonstrates Greater Efficacy in Patients Identified Using More Sensitive CCR5 Tropism Test

1/12/2010

CCR5 Antagonist Vicriviroc Demonstrates Long-Term Safety and Efficacy at 96 Weeks
9/14/2009

Assessment of Pharmacokinetic and Safety Interactions Between Vicriviroc and CYP3A4 Substrates, Inhibitors, and Inducers

9/14/2009

Clonal Analysis of the gp120 V3 Loop from Clinical Isolates Displaying Phenotypic Resistance to Vicriviroc
9/14/2009

Vicriviroc Long-term Safety and Efficacy: 96-Week Results from the VICTOR-E1 Study
9/14/2009

Comparison of Trofile« and ViroTectTropism Assays in Treatment-Experienced Subjects
2/10/09.

Rapamycin Enhances Anti-HIV Activity of Experimental CCR5 Antagonist Vicriviroc
1/16/09

Long-term Safety of Vicriviroc
11/05/2008


Low Doses of CCR5 Antagonist Vicriviroc Do Not Suppress HIV as well as Efavirenz (Sustiva) in Treatment-naive Patients; New Study Underway
10/14/08


Schering-Plough Initiates Phase II Study with Vicriviroc in Treatment-na´ve HIV-infected Patients
4/16/08

CCR5 Antagonist Vicriviroc Shows Continued Benefits and Good Tolerability at 48 Weeks: VICTOR-E1 Trial
2/05/08

Vicriviroc, a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral Replication in Treatment-Experienced Adults: VICTOR-E1 48-week Results.
2/10/08

Vicriviroc, a Next Generation CCR5 Antagonist, Exhibits Potent, Sustained Suppression of Viral Replication in Treatment-Experienced Adults: VICTOR-E1 48-week Results
2/05/08

Effect of Virus Concentration on in vitro Measurement of Phenotypic Resistance to the CCR5 Antagonist Vicriviroc.
2/05/08

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children